What is Hertraz (Trastuzumab)?
Trastuzumab is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high risk feature.
Trastuzumab is a type of immunotherapy known as a monoclonal antibody. A monoclonal antibody is a man-made version of an immune system protein that fits like a lock and key with one certain protein.
Trastuzumab is designed to seek out and lock onto a protein called human epidermal growth factor receptor 2 (HER2), which is located on certain cells in the body. About 1 out of 4 breast and stomach cancers have higher than normal numbers of these receptors on their cells’ surfaces. Once trastuzumab attaches to these cells, it brings in other immune cells to help kill them.
440mg (1 Vial)
Storage and handling:
Store the vials at 2°- 8° C
How do we source the Drug?
SSPWL sources its drug through its efficient network, across the globe, and ensure the delivery is prompt. However, a valid prescription from the treating Oncologist is mandatory, with all relevant documents associated with its procurement is essential.
Company that Manufactures/ Markets:
M/s Roche Products Pvt. Ltd.
Call: +91 07738100125 / +91 07738151650 or